RNTX

MKT CAP:$49M

Rein Therapeutics Inc.

Market Cap

$49M

Healthcare·Medical - Pharmaceuticals·🇺🇸 United States·NASDAQ

Healthcare·Medical·🇺🇸·NASDAQ

Stock Price

$1.79+$0.54 (+43.20%)

Apr 21, 2026

Company Details

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product ca...

CEO

James Brian Windsor

IPO Date

Jun 29, 2017

Website

www.reintx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$50M

EPS (Diluted)

-$2,511.76

Free Cash Flow

-$19M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 26, 2026

$0EPS -$1.96

Q4 2025

Mar 26, 2026

$0EPS -$1.22

Q3 2025

Nov 14, 2025

$0EPS -$0.21

Q2 2025

Aug 14, 2025

$0EPS -$0.28

Q1 2025

Mar 31, 2025

$0EPS -$2,510.05

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 24	$0	$0	-$6M
Q4 24	$0	$0	-$6M
Q1 25	$0	$0	-$6M
Q2 25	$0	$0	-$7M
Q3 25	$0	$0	-$5M
Q4 25	$0	$0	-$4M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 20	-$5M	-$5M
Q1 21	-$6M	-$7M
Q2 21	-$4M	-$4M
Q3 21	-$7M	-$7M
Q4 21	-$6M	-$6M
Q1 22	-$8M	-$8M
Q2 22	-$6M	-$6M
Q3 22	-$7M	-$7M
Q4 22	-$4M	-$4M
Q1 23	-$5M	-$5M
Q3 24	-$4M	-$4M
Q4 24	-$5M	-$5M
Q1 25	-$6M	-$6M
Q2 25	-$6M	-$6M
Q3 25	-$4M	-$4M
Q4 25	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q4 20	$0
Q1 21	$85.0K
Q2 21	$67.0K
Q3 21	$5.0K
Q4 21	$0
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 25	—	-9.5%
Q4 25	—	-31.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 20	$363.0K	—
Q1 21	$631.0K	—
Q2 21	$362.0K	—
Q3 21	$660.0K	—
Q4 21	$607.0K	—
Q1 22	$689.0K	—
Q2 22	$528.0K	—
Q3 22	$442.0K	—
Q4 22	$424.0K	—
Q1 23	$391.0K	—
Q3 24	$508.0K	—
Q4 24	$133.0K	—
Q1 25	$264.0K	—
Q2 25	$256.0K	—
Q3 25	$1M	—
Q4 25	$257.0K	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 24	$4M	—	$2M
Q4 24	$3M	—	$2M
Q1 25	$3M	$3M	—
Q2 25	$4M	$3M	—
Q3 25	$2M	—	$4M
Q4 25	$2M	$2M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$7M	$31M	$38M
Q2 22	$8M	$25M	$32M
Q3 22	$5M	$21M	$25M
Q4 22	$5M	$16M	$21M
Q1 23	$8M	$9M	$17M
Q2 23	$13M	$499.0K	$14M
Q3 23	$12M	$0	$12M
Q4 23	$17M	$0	$17M
Q1 24	$12M	$0	$12M
Q2 24	$22M	$0	$22M
Q3 24	$18M	$0	$18M
Q4 24	$13M	$0	$13M
Q1 25	$7M	$0	$7M
Q2 25	$6M	$0	$6M
Q3 25	$4M	$0	$4M
Q4 25	$3M	$0	$3M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 24	22M	—	—
Q4 24	22M	+0.1%	—
Q1 25	2M	-89.9%	—
Q2 25	24M	+1003.9%	—
Q3 25	26M	+9.0%	+21.7%
Q4 25	25M	-3.5%	+17.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 24	$0	15
Q4 24	$0	11
Q1 25	$0	11
Q2 25	$0	11
Q3 25	$0	11
Q4 25	$0	100K

Revenue / Employee